Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term study of Palforzia in peanut allergy
NCT03292484Phase 3Completed
- Start
- Nov 2017
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of peanut protein in peanut allergy. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 59 months, Number of Participants With Premature Discontinuation of AR101 Dosing Due to TEAEs up to 59 months and 4 more. Started Nov 2017; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03292484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292484.